Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

Journal of Thoracic Oncology

English

P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P2.09-03 Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection

Journal of Thoracic Oncology

English

P018 Afatinib Named Patient Use Program in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology

English

P082 DNA Methylation: A More Sensitive Marker for Treatment Monitoring?

Journal of Thoracic Oncology

English

P3.01-21 Metastatic Lung Carcinoma —An Institutional Experience From Eastern India

Journal of Thoracic Oncology

English

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology

English

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology

English

P3.15-18 Comparison of Pain Control Effects and Side Effects Early After VATs Lobectomy Between IV-PCA, Epidural-Pca and On-Q

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer

P2.09-03 Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection

P018 Afatinib Named Patient Use Program in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

P082 DNA Methylation: A More Sensitive Marker for Treatment Monitoring?

P3.01-21 Metastatic Lung Carcinoma —An Institutional Experience From Eastern India

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

P3.15-18 Comparison of Pain Control Effects and Side Effects Early After VATs Lobectomy Between IV-PCA, Epidural-Pca and On-Q